AntiOp Partners With Reckitt Benckiser Pharmaceuticals Inc. To Develop Nasally Administered Treatment For Opioid Overdose
5/21/2014 9:24:36 AM
LEXINGTON, Ky.--(BUSINESS WIRE)--AntiOp, Inc., a Kentucky company founded by Dr. Daniel Wermeling, has signed an agreement with Reckitt Benckiser Pharmaceuticals, Inc. to accelerate production and worldwide marketing of intranasal naloxone, a drug designed to treat opioid overdose.
Help employers find you! Check out all the jobs and post your resume.
comments powered by